Literature DB >> 25813012

#36: Prenatal aneuploidy screening using cell-free DNA.

.   

Abstract

Recent advances in technology have created exciting opportunities to expand and improve genetic testing options that are available to women during pregnancy. However, the novelty and complexity of these technologies, combined with the commercial interest to implement these tests rapidly into routine clinical care, have created challenges for physicians and patients and potentially will lead to misunderstanding, misuse, and unintended consequences. The purpose of this document was to aid clinicians in their day-to-day practice of counseling patients regarding prenatal aneuploidy testing options with cell-free DNA screening, which includes how it compares to current testing methods, potential benefits and harms, and its limitations and caveats.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25813012     DOI: 10.1016/j.ajog.2015.03.043

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

Review 1.  Pre- and post-test genetic counseling for chromosomal and Mendelian disorders.

Authors:  Jill Fonda Allen; Katie Stoll; Barbara A Bernhardt
Journal:  Semin Perinatol       Date:  2015-12-21       Impact factor: 3.300

2.  The Integration of Noninvasive Prenatal Screening into the Existing Prenatal Paradigm: a Survey of Current Genetic Counseling Practice.

Authors:  Emily Suskin; Laura Hercher; Kathleen Erskine Aaron; Komal Bajaj
Journal:  J Genet Couns       Date:  2016-02-15       Impact factor: 2.537

3.  Primary Cesarean Delivery Patterns among Women with Physical, Sensory, or Intellectual Disabilities.

Authors:  Blair G Darney; Frances M Biel; Brian P Quigley; Aaron B Caughey; Willi Horner-Johnson
Journal:  Womens Health Issues       Date:  2017-01-18

4.  About one-half of early spontaneous preterm deliveries can be identified by a rapid matrix metalloproteinase-8 (MMP-8) bedside test at the time of mid-trimester genetic amniocentesis.

Authors:  Sun Min Kim; Roberto Romero; JoonHo Lee; Piya Chaemsaithong; Min-Woo Lee; Noppadol Chaiyasit; Hyo-Jin Lee; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-12-07

5.  Cell-free DNA screening in clinical practice: abnormal autosomal aneuploidy and microdeletion results.

Authors:  Stephanie G Valderramos; Rashmi R Rao; Emily W Scibetta; Neil S Silverman; Christina S Han; Lawrence D Platt
Journal:  Am J Obstet Gynecol       Date:  2016-06-28       Impact factor: 8.661

6.  Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2019-02-19

7.  Diagnostic cytogenetic testing following positive noninvasive prenatal screening results: a clinical laboratory practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Athena M Cherry; Yassmine M Akkari; Kimberly M Barr; Hutton M Kearney; Nancy C Rose; Sarah T South; James H Tepperberg; Jeanne M Meck
Journal:  Genet Med       Date:  2017-07-20       Impact factor: 8.822

8.  Obstetrician and Gynecologist Utilization of the Noninvasive Prenatal Testing Expanded Option.

Authors:  Sarah Mayes; Syed Hashmi; Mark A Turrentine; Sandra Darilek; Lara A Friel; Jennifer Czerwinski
Journal:  AJP Rep       Date:  2015-10-29

9.  Sociodemographic and attitudinal predictors of simultaneous and redundant multiple marker and cell-free DNA screening among women aged ⩾35 years.

Authors:  A K Lewkowitz; A J Kaimal; K Thao; A O'Leary; O Nseyo; M Kuppermann
Journal:  J Perinatol       Date:  2017-05-11       Impact factor: 2.521

10.  Chromosomal microarray analysis for pregnancies with abnormal maternal serum screening who undergo invasive prenatal testing.

Authors:  Xiaoqing Wu; Ying Li; Na Lin; Xiaorui Xie; Linjuan Su; Meiying Cai; Yuan Lin; Linshuo Wang; Meiying Wang; Liangpu Xu; Hailong Huang
Journal:  J Cell Mol Med       Date:  2021-05-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.